Vesalius Biocapital Partners
Investor profile
Venture capital
Also recorded as: Vesalius Biocapital
Deals
10
distinct rounds
Companies
9
backed
Active span
2018–2025
8 yrs
Total round €
€342M
sum of rounds joined
Deals by year
distinct rounds / yearTop sectors
by dealsStages
by dealsCountries
by dealsCo-investment network
shared roundsHover a node for shared-deal counts; click a co-investor to open its profile.
Frequent co-investors
shared rounds- Adjuvant Capital2
- BioMedPartners2
- Fresenius Medical Care Ventures2
- GF Group Holding2
- Swisscanto Invest2
- Verve Ventures2
- Aescuvest1
- Armilar Venture Partners1
- Beta Capital1
- BioGeneration Ventures1
- BIONIQ Capital1
- BlackRock Innovation Capital1
- Cure Capital1
- EIR Ventures1
- Forbion1
- Indico Capital Partners1
- INKEF Capital1
- Lauxera Capital Partners1
- Lince Capital1
- MTIP AG1
- Nordic Life Science1
- Optum Ventures1
- Oxford Science Enterprises1
- PFM Health Sciences1
- Pictet Alternative Advisors1
Portfolio
top 30 by total round €| Company | Country | Rounds | Total € |
|---|---|---|---|
| Caresyntax | Germany | 1 | €164M |
| Memo Therapeutics | Switzerland | 2 | €61M |
| Scenic Biotech | Netherlands | 1 | €28M |
| Topas Therapeutics | Germany | 1 | €22M |
| Oncodna | Belgium | 1 | €19M |
| OMEICOS | Germany | 1 | €17M |
| Rejuvenate Boimed | Belgium | 1 | €16M |
| Nutrium | Portugal | 1 | €12M |
| tonic app | Portugal | 1 | €3.5M |
Biggest deals
top 10 by amount| Company | Stage | Amount | Date |
|---|---|---|---|
| Caresyntax | Series C | €164M | 2024-08 |
| Memo Therapeutics | Series B | €35M | 2022-02 |
| Scenic Biotech | Series A | €28M | 2022-03 |
| Memo Therapeutics | Series C | €26M | 2023-11 |
| Topas Therapeutics | Series B | €22M | 2020-10 |
| Oncodna | Series B | €19M | 2020-02 |
| OMEICOS | Series C | €17M | 2018-09 |
| Rejuvenate Boimed | Series B | €16M | 2021-10 |
| Nutrium | Series A | €12M | 2025-09 |
| tonic app | Other | €3.5M | 2019-09 |